ZVRA

Zevra's FY2025 results look transformative on the surface: revenue jumped 350.9% to $106M and net income swung to +$83.2M from -$106M, driving a headline P/E of 9.9x. But the MD&A makes clear the profit is not operational — the company sold its rare pediatric disease priority review voucher (PRV) on April 1, 2025 for $148.3M in net proceeds, which mechanically converts a money-losing commercial-stage biotech into a 'profitable' one for a single year. Strip that out and operating income remains -$62.9M (operating margin -59.1%), and operating cash flow is still -$1.6M despite the cash windfall. The 78.2% net margin and 53.8% ROE are accounting artifacts, not durable economics.

The underlying business case rests on MIPLYFFA, the FDA-approved (Sept 2024) treatment for Niemann-Pick disease type C that became commercially available in November 2024 — so FY2025 was effectively the first full launch year. The MAA was filed with the EMA in July 2025 and is under review, which could materially expand the addressable market. OLPRUVA (UCDs, acquired via Acer in Nov 2023) is also marketed, and celiprolol for VEDS sits in the pipeline. Balance sheet has strengthened meaningfully — equity tripled to $155M, current assets up 159.2% to $223M, cash $62.4M — giving real runway. Long-term debt of $61.9M is manageable against equity.